Homepage
Author:
Context Therapeutics Inc.
Posted Date:
May 6, 2026
Context Therapeutics Reports First Quarter 2026 Operating and Financial Results
Context Therapeutics Inc.
May 6, 2026
Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer
Context Therapeutics Inc.
April 2, 2026
Context Therapeutics Reports Full Year 2025 Operating and Financial Results
Context Therapeutics Inc.
March 23, 2026
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026
Context Therapeutics Inc.
March 19, 2026
Context Therapeutics to Participate in Upcoming Investor Conferences
Context Therapeutics Inc.
February 9, 2026
